Status:
UNKNOWN
Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.
Lead Sponsor:
Asoc. Prof. Erdoğan Selçuk Şeber
Conditions:
Is the Coronovac Vaccine Effective in Patients Receiving Chemotherapy
Eligibility:
All Genders
18-90 years
Brief Summary
This study aimed to investigate the effectiveness of CoronaVac vaccine, which is more than 90% protective in healthy people, in cancer patients receiving active chemotherapy. In this study, to collect...
Eligibility Criteria
Inclusion
- Group 1
- 18 years old and above
- Having completed two doses of CoronoVac vaccine on time
- Those with a pathological diagnosis of breast cancer or lung cancer
- Being the first dose of vaccine during active chemotherapy period
- Ecog performance score 0-1
- Patients who signed the informed voluntary consent form
- Group 2
- Over 18 years old
- Ecog performance score is 0-1
- Those who have completed 2 doses of coronovac vaccine within the recommended period
- Volunteer who signed the informed consent form
Exclusion
- For all groups
- Being confirmed or suspected covid-19 before vaccination
- Symptomatic covid-19 infection
- Being addicted to alcohol or drugs
- Having a fever of 37.8 ° C as a suspect before vaccination
- Aspleni
Key Trial Info
Start Date :
March 31 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2022
Estimated Enrollment :
291 Patients enrolled
Trial Details
Trial ID
NCT04765215
Start Date
March 31 2021
End Date
March 31 2022
Last Update
June 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tekirdağ Namık Kemal ÜNiversitesi
Tekirdağ, Turkey (Türkiye)